BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting [Yahoo! Finance]
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement [Yahoo! Finance]